Plain-English translation of NCT05659797 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging technique called FES PET/DBT that uses a radioactive tracer to help doctors see breast cancer that is estrogen-receptor positive (a type that grows in response to estrogen). The scan is designed to show doctors exactly where the cancer is in the breast and how much disease is present, which could help plan surgery better. Researchers want to see how well this new imaging method works compared to standard imaging tests.
Currently, doctors use several different imaging tools to find breast cancer, but they don't always show the full picture of where cancer is located within the breast. This new imaging technique may provide more detailed information about estrogen-responsive cancer, which could help surgeons plan better treatment and make sure they remove all the cancer.
You likely qualify if…
You likely don't qualify if…
You will come in for an imaging session where you will receive an injection of a small amount of radioactive tracer (similar to tracers used in standard PET scans). You will then lie still while the specialized scanner takes detailed images of your breast. The entire visit will take a few hours. Some participants may also be invited to have images compared with a whole-body PET scan, which would not require an additional injection.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States